Kurma leads €17m series-B round for Stat Diagnostica

Kurma joined Idinvest, Boehringer Ingelheim Venture Fund and Caixa Capital Risc as new investors in Stat Diagnostica. The funding round also saw participation from existing backers Ysios Capital and Axis Participaciones Empresariales.

Ysios has significantly increased its stake in the company to become the largest shareholder.

The fresh funding will allow the firm to prepare for European market launch in 2015.

Previous funding
In 2011, Ysios and Axis provided Stat Diagnostica with €2m in a series-A funding round to finance the initial development of the firm's diagnostics solution.

Company
Founded in 2010 and based in Barcelona, Stat Diagnostica is focused on development testing solutions where fast and accurate diagnosis is needed. The firm aims to develop point-of-care diagnostics solutions that reduce diagnosis waiting times from several days to less than 30 minutes. Its in vitro diagnostic system consolidates molecular and immunoassay techniques in a single device.

People
Raúl Martin-Ruiz is an investment director at Ysios. Rémi Droller is managing partner at Kurma.

Advisers
Equity – Grant Thornton (Corporate finance); Cuatrecasas (Legal).
Company – Rousaud Costas Duran (Legal)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Early-stage
• Spain
• Ysios Capital
• Caixa Capital Risc